In the quiet arithmetic of a long fight against a virus that refuses to be fully tamed, a study from Lesotho offers a measured note of steadiness. Presented at HIV Glasgow 2026 by Professor Niklaus Labhardt on behalf of Dr Anna Klicpera and colleagues, it found dolutegravir resistance in 8% of people whose virus kept appearing on repeated testing and who had resistance results on hand. Set against the same cohort three years earlier, where no rise appeared, the finding suggests that a key medicine is still holding its ground in this setting, though the work itself remains unfinished.
Dolutegravir Resistance Holds Steady at 8% in Lesotho Cohort, Study Finds
No increase in dolutegravir resistance over three years in the same cohort
Mark
So what is the headline here? Resistance to dolutegravir is 8%?
Mimi
Yes, but in a specific group: people in a Lesotho study whose viral loads stayed detectable on repeated tests and who had resistance results. And that figure is no higher than the same cohort showed three years ago.
Mark
Why does the comparison matter more than the number itself?
Mimi
Because the worry with any widely used drug is a rising trend. Flat over three years is reassuring.
Luke
I'd keep the reassurance modest. The 8% only covers people with resistance test results, so it says nothing about everyone on dolutegravir. And we aren't told how many people that is.
Mark
What about the finding that most resistant people were also resistant to other drugs?
Mimi
It means resistance usually wasn't isolated to dolutegravir. It showed up alongside resistance to drugs it is often combined with.
Luke
Right, though the report doesn't say which drugs, or how many people were in that group. I wouldn't read more into it than that.
Mark
And the study is still going?
Mimi
It is, so this is a progress report, not a final verdict.
Luke
Agreed. Stable so far, in this cohort, is what the reporting supports. It doesn't tell us about other countries.
Der Puls
- A small but persistent group of people in Lesotho, whose virus keeps showing up despite treatment, is where the worrying signal of drug resistance is being sought.
- The discovery of resistance in 8% of these individuals raises the question of whether dolutegravir, a cornerstone medicine, is beginning to lose its edge.
- Researchers have checked the figure against the same cohort three years ago and found no climb, steadying the alarm before it spreads.
- Most resistant individuals also resist other drugs often paired with dolutegravir, a pattern that complicates the path to next-line choices.
- The study is still running, so the picture is a snapshot in motion, with the key watch point being whether the 8% holds level.
In the quiet arithmetic of a long fight against a virus that refuses to be fully tamed, a study from Lesotho offers a measured note of steadiness. Presented at HIV Glasgow 2026 by Professor Niklaus Labhardt on behalf of Dr Anna Klicpera and colleagues, it found dolutegravir resistance in 8% of people whose virus kept appearing on repeated testing and who had resistance results on hand. Set against the same cohort three years earlier, where no rise appeared, the finding suggests that a key medicine is still holding its ground in this setting, though the work itself remains unfinished.
At the HIV Glasgow 2026 conference, Professor Niklaus Labhardt of University Hospital Basel brought forward a finding from Lesotho. Among people in an ongoing study whose viral loads stayed detectable on repeated testing and who had resistance results available, 8% showed resistance to dolutegravir. The work was led by Dr Anna Klicpera and her colleagues, and Labhardt presented it for them.
The group behind that number is narrow. It does not describe everyone on dolutegravir, only those whose virus was still replicating despite treatment, the people where resistance would most plausibly appear. Compared with the same cohort three years earlier, the researchers saw no increase, so the figure does not point to a climbing trend in this setting over that span.
Most of those with dolutegravir resistance also resisted other HIV drugs commonly used alongside it, so the problem was not confined to a single drug. The source report does not give the cohort size, the number tested, or the other drugs involved. For now, the result suggests dolutegravir is holding its effectiveness in this population, and the study will continue to show whether that stability lasts.
At the HIV Glasgow 2026 conference, Professor Niklaus Labhardt of University Hospital Basel presented a finding from Lesotho: among people in an ongoing study who had repeatedly detectable viral loads and a resistance test result, 8% showed resistance to dolutegravir.
The work was led by Dr Anna Klicpera and colleagues, and Labhardt presented it on the team's behalf. The study is still running, so the figures come from a project in progress, not a closed dataset.
The group of people the 8% describes is specific. It does not cover everyone taking dolutegravir. It covers those whose viral loads stayed detectable on repeated testing and who also had resistance test results available. These are the people in whom resistance would most plausibly turn up, because the virus is still replicating despite treatment.
The researchers compared this result with the rate of dolutegravir resistance found in the same cohort three years ago. They saw no increase. The 8% is therefore not a sign of a climbing trend in this setting, at least over that interval.
The study also looked at what accompanied the resistance. Most people who had resistance to dolutegravir also had resistance to other HIV drugs that dolutegravir is often combined with. Resistance in these cases was not confined to a single drug in the regimen.
The source is a short report on the conference presentation and points readers to a fuller news story from aidsmap. It does not give the size of the cohort, the number of people tested, or the drugs involved beyond dolutegravir. The percentage is best read as a snapshot from a study still collecting data.
For now, the Lesotho result points to dolutegravir holding its effectiveness in this population, with resistance stable over three years. As the study continues, the thing to watch is whether the 8% stays level and whether the pattern of resistance to partner drugs persists.
Bemerkenswerte Zitate
Most people with dolutegravir resistance also had resistance to other HIV drugs it is often combined with.— Findings presented from the Klicpera study at HIV Glasgow 2026 (paraphrased)
Möchten Sie die ganze Geschichte?
Das Original lesen bei European AIDS Treatment Group ↗